CALYPTE, WKN:909402 *CALY* DIE VER-10-FACHUNG im BIO-HYPE - 500 Beiträge pro Seite

[DieNEUE]

-CALY macht einen HIV-Test auf Urin Basis mit 99,7 % sicherer Diagnose-PUNKT-
-CALY hat Cash verbraten, da die Laboranten Lohn bekommen -PUNKT-
-CALY könnte aus humanitären Gründen vom Staat Amerika sanktioniert werden-PUNKT-
-CALY kam unter die Räder wie andere Aktien auch-PUNKT-
-Das Thema AIDS ist TOP AKUELL , siehe Nkosi Johnson -PUNKT-
- Die Zahl der Aids-Infizierten wird in Südafrika im kommenden Jahrzehnt voraussichtlich von derzeit mehr als vier auf sieben Millionen steigen. -PUNKT-
- An der Immunschwächekrankheit sterben jährlich 2,8 Millionen Menschen.-PUNKT-
- Mehr als 70 Prozent der weltweit mit dem AIDS-Virus infizierten Menschen leben auf dem schwarzen Kontinent.
-Dec 1, 2000—On World AIDS Day,Calypte tests used in new testing and treatment strategy in South Africa -PUNKT-
-Ebenfalls im Dezember gab die Weltbank zusammen mit dem IWF und einigen Gläubigerstaaten einen Schuldenerlaß bekannt: Für 22 Länder, unter ihnen viele in Afrika, stehen 42 Milliarden US-$ zur Verfügung, weitere 28 Milliarden US-$ sollen entsprechend vergeben werden. -PUNKT-

ENDE
DieNEUE

[DieNEUE]

Market Cap (Mil) $ : 5.41 -PUNKT-
Employees: 65 (12/31/2000) -PUNKT-

http://www.marketguide.com/mgi/signdevt.asp?nss=www&rt=signd…
Calypte Biomedical Corp.
NASD : CALY
Sector: Technology
Industry: Scientific & Technical Instr.


 Calypte Biomedical Corp. Sells Minority Stake in Pepgen April 23, 2001
Calypte Biomedical Corp. announced that it has sold its 29% minority position in Pepgen Corporation, a privately held therapeutic company, for $500,000. Calypte`s decision to sell its Pepgen stake reflects the company`s commitment to its core diagnostics business and provides immediate access to cash needed to pay down debt and finance expenditures.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. Announces First Quarter Revenues and Status April 12, 2001
Calypte Biomedical Corp. announced that its preliminary first quarter revenues for the three months ended March 31, 2001 had exceeded its previous best quarter. At the same time, the Company stated that it does not believe that its currently-available financing will be adequate to sustain operations at current levels through the second quarter of 2001. In addition, the Company is currently in discussions with the staff of Nasdaq regarding the Company`s failure to meet the net tangible asset requirement for continued listing on the Nasdaq SmallCap Market set forth in the Nasdaq Marketplace Rules.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. In Distribution Pact February 06, 2001
Calypte Biomedical Corp. announced that beginning this month, Organon Teknika Corporation, a provider of in vitro diagnostics, will distribute worldwide an HIV-1 Western Blot serum (blood) assay manufactured by Calypte Biomedical. Organon Teknika will distribute the test non-exclusively under Calypte`s Cambridge Biotech tradename. The long-term arrangement calls for minimum monthly shipments, significantly increasing Calypte`s serum Western Blot sales volume.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. Alameda Manufacturing Facility Approved by FDA: Alameda Facility Will Allow Increased Production of HIV-1 Antibody Urine Test January 22, 2001
Calypte Biomedical Corp. announced that it has been granted "pre-market approval" by the U.S. Food and Drug Administration (FDA) for the production, effective immediately, of the Company`s HIV-1 Urine EIA product in its manufacturing plant in Alameda, California. The facility, which is equipped with updated manufacturing technology and is larger than Calypte`s current plant in Berkeley, will significantly increase the Company`s production and distribution capabilities.
--------------------------------------------------------------------------------
 International Studies Demonstrate Calypte Biomedical Corp.`s Modified HIV-1 Antibody Urine Test Competitive With Serum Testing December 20, 2000
Calypte Biomedical Corp. announced the results of two independent, international studies that examined the accuracy of the Company`s modified HIV-1 antibody urine test. Results of both studies of Calypte`s test demonstrated high concordance with serum (blood) testing, which has long been held to be the gold standard in HIV testing.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. New California Manufacturing Facility Gains State Approval - Company Expands Distribution Into Developing Countries December 20, 2000
Calypte Biomedical Corp. announced that its new manufacturing plant, based in Alameda, has received a Manufacturing License from the California Department of Health Services Food and Drug Branch. The California manufacturing license permits Calypte to manufacture its modified assay for worldwide export from its Alameda facility.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. and Becton, Dickinson and Company Announce New One-stop Testing Service December 04, 2000
Calypte Biomedical Corp. announced a joint promotional effort together with BD, whereby the companies are to co-promote the Sentinel family of testing services for urine-based testing for human immunodeficiency virus (HIV), chlamydia, and gonorrhea.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. Biomed, Osborn Science In Development Pact November 02, 2000
Calypte Biomedical Corp. announced that it is collaborating with the Osborn Scientific Group to develop two urine-based rapid HIV antibody tests. Once the assays are completed and have received regulatory clearance, Calypte and Osborn expect the products to be the first urine-based rapid HIV antibody tests.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced that its HIV-1 antibody urine test has been approved by the State Drug Administration of the People`s Republic of China, making it the only urine-based HIV-1 test... August 24, 2000
Calypte Biomedical Corp. announced that its HIV-1 antibody urine test has been approved by the State Drug Administration of the People`s Republic of China, making it the only urine-based HIV-1 test approved for distribution within China. Calypte`s HIV urine test offers significant advantages over traditional HIV blood tests because unlike blood, no medical training is required to collect urine samples. In addition, the safety of both the patient and healthcare personnel are enhanced because the urine of HIV-infected people does not appear to harbor the infectious virus itself - only the harmless antibody that signifies prior exposure to HIV.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced the expansion of its innovative mobile HIV-1 antibody urine testing program from South Africa to 41 countries in sub-Saharan Africa. August 09, 2000
Calypte Biomedical Corp. announced the expansion of its innovative mobile HIV-1 antibody urine testing program from South Africa to 41 countries in sub-Saharan Africa.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced that David Collins has replaced William Boeger as Chairman and Nancy Katz was appointed Chief Executive Officer. June 13, 2000
Calypte Biomedical Corp. announced that David Collins has replaced William Boeger as Chairman and Nancy Katz was appointed Chief Executive Officer.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced it has partnered with the Chinese National Center for AIDS Prevention and Control (NCAIDS) through Beijing HuaAi Science and Technology Development Co. Ltd. to... June 12, 2000
Calypte Biomedical Corp. announced it has partnered with the Chinese National Center for AIDS Prevention and Control (NCAIDS) through Beijing HuaAi Science and Technology Development Co. Ltd. to distribute the first HIV-1 antibody urine test within the People`s Republic of China. Once approved by the State Drug Administration of China (SDA), Calypte`s test will be the only urine-based HIV-1 test distributed within the People`s Republic of China. Calypte`s application has been submitted to the SDA and is currently in process, with approval expected by the end of 2000.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced today the appointment of American Edge Medical Company as the exclusive distributor of its urine HIV-1 antibody testing products in South Africa. American Edge... June 06, 2000
Calypte Biomedical Corp. announced today the appointment of American Edge Medical Company as the exclusive distributor of its urine HIV-1 antibody testing products in South Africa. American Edge has partnered with African Medical Solutions, a South African company formed specifically to market Calypte`s products in that country.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced that it has entered into an exclusive distribution agreement with privately held Biobras S.A. of Brazil to distribute its HIV urine-based testing products... May 11, 2000
Calypte Biomedical Corp. announced that it has entered into an exclusive distribution agreement with privately held Biobras S.A. of Brazil to distribute its HIV urine-based testing products throughout Brazil.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced that its Sentinel testing service, the first and only urine-based testing service dedicated exclusively to the detection of exposure to HIV-1, chlamydia, and... May 10, 2000
Calypte Biomedical Corp. announced that its Sentinel testing service, the first and only urine-based testing service dedicated exclusively to the detection of exposure to HIV-1, chlamydia, and gonorrhea sexually transmitted diseases (STDs), is now available throughout the United States. The service offers healthcare providers and patients a new fast, affordable and painless testing method for STDs. Calypte is developing a Sentinel testing service web site that will enable medical professionals and authorized institutions to order testing services directly over the Internet. The site is expected to be operational by May 12, 2000.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced that Dr. Howard Urnovitz, Calypte`s Founder and Chief Scientific Officer, and William Boeger, Calypte`s Chairman, have established a new commercial company, named... March 09, 2000
Calypte Biomedical Corp. announced that Dr. Howard Urnovitz, Calypte`s Founder and Chief Scientific Officer, and William Boeger, Calypte`s Chairman, have established a new commercial company, named Chronix Biomedical, that will focus on novel ways to detect aberrant genes in individuals with chronic diseases. Chronix will be financed independently of Calypte, but Calypte will retain rights to any urine diagnostic tests that result from its research efforts. Both Dr. Urnovitz and Mr. Boeger will maintain their current positions at Calypte.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced that it has entered into a collaboration with Wampole Laboratories, a division of Carter Wallace, Inc., and Clinical Reference Laboratory (CRL) to launch a new... January 24, 2000
Calypte Biomedical Corp. announced that it has entered into a collaboration with Wampole Laboratories, a division of Carter Wallace, Inc., and Clinical Reference Laboratory (CRL) to launch a new national urine-based testing service for HIV-1 antibody, chlamydia, and gonorrhea. The new service, called Sentinel, is a painless, non-invasive, urine-based sampling method designed to identify HIV-1 antibody and the chlamydia and gonorrhea sexually transmitted diseases (STDs).
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced that the United States Food and Drug Administration approved a Day Assay license supplement to its "Cambridge Biotech" Human Immunodeficiency Virus Type 1 (HIV-1)... November 19, 1999
Calypte Biomedical Corp. announced that the United States Food and Drug Administration approved a Day Assay license supplement to its "Cambridge Biotech" Human Immunodeficiency Virus Type 1 (HIV-1) Western Blot test.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced that it has signed a definitive distribution agreement that will give Carter-Wallace, Inc. the exclusive United States sales and marketing rights for the... September 16, 1999
Calypte Biomedical Corp. announced that it has signed a definitive distribution agreement that will give Carter-Wallace, Inc. the exclusive United States sales and marketing rights for the Company`s HIV products in the hospital, public health and reference lab markets. Terms were not announced.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced that it has selected four new distributors for its urine HIV-1 screening EIA and Western blot supplemental tests. Together, the distributors will have exclusive... August 11, 1999
Calypte Biomedical Corp. announced that it has selected four new distributors for its urine HIV-1 screening EIA and Western blot supplemental tests. Together, the distributors will have exclusive distribution rights in 13 countries throughout the Middle East, Eastern Europe and Asia. Combined, the distribution agreements call for minimum purchases of 670,000 screening tests and more than 8, 000 Western blot supplemental tests.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced that one of its newly acquired operating units, located in Rockville, Maryland, received a warning letter from the United States Food and Drug Administration. The... May 14, 1999
Calypte Biomedical Corp. announced that one of its newly acquired operating units, located in Rockville, Maryland, received a warning letter from the United States Food and Drug Administration. The warning letter was based upon an inspection of the Rockville manufacturing facility, which cited a number of significant observations. The facility was owned and operated at the time of the inspection by Cambridge Biotech Corp.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. and Carter-Wallace, Inc. announced that they have signed a letter of intent that will give Carter-Wallace the exclusive United States sales and marketing rights for Calypte... April 12, 1999
Calypte Biomedical Corp. and Carter-Wallace, Inc. announced that they have signed a letter of intent that will give Carter-Wallace the exclusive United States sales and marketing rights for Calypte Biomedical`s HIV products in the hospital, public health and reference lab markets.
--------------------------------------------------------------------------------
 The Chinese National Center for AIDS Prevention and Control announced that it has selected Calypte Biomedical Corp.`s non-invasive urine HIV test for wide-scale use within the Chinese health-care... March 11, 1999
The Chinese National Center for AIDS Prevention and Control announced that it has selected Calypte Biomedical Corp.`s non-invasive urine HIV test for wide-scale use within the Chinese health-care system.
--------------------------------------------------------------------------------
 Calypte Biomedical Corp. announced that its affiliated therapeutic Company, Pepgen Corp., will begin Phase I clinical trials of its oral interferon, Interferon Tau, in multiple sclerosis patients. February 25, 1999
Calypte Biomedical Corp. announced that its affiliated therapeutic Company, Pepgen Corp., will begin Phase I clinical trials of its oral interferon, Interferon Tau, in multiple sclerosis patients.

[DieNEUE]

ENTSCHULDIGUNG nicht Sanktion sondern Subvention.
Also nun richtig.
-CALY könnte aus humanitären Gründen vom Staat Amerika subventieoniert werden -PUNKT-

Fazit : Die Welt kann auf den HIV Test von CALY nicht verzichten und dementsprechend wird etwas in die angedachte Richtung passieren.

MfG
DieNEUE

[DieNEUE]

Amex Biotech im Aufwärtskanal

Markttechnik sieht Seitwärtsbewegung mit kurzfristigem

Aufwärtsdrang

Nach dem Bruch des mittleren Abwärtstrends hat der Auswahlindex einen
Trendkanal ausgebildet. Zur Fortsetzung der Aufwärtsbewegung muss der
Widerstand bei 645 Punkten überwunden werden.

Einen Monat ist es her, dass der amerikanische Biotechnologieindex Amex
Biotech (BTK) den mittelfristigen Abwärtstrend (grün) gebrochen hat. Das daraus
resultierende Kaufsignal (blauer Pfeil, siehe auch letzte Analyse ) hätte bisher
in der Spitze einen Gewinn von 18 Prozent eingebracht. In den vergangenen
beiden Wochen konsolidierte der Index diesen Anstieg. Mit Spannung darf nun
beobachtet werden, wie die Biotechwerte weiter performen.


Denn in der Zwischenzeit hat sich ein Trendkanal (lila) geformt, der weitere
Kursanstiege verspricht. Die obere Begrenzung dieser Chartformation liegt
momentan bei 685 Punkten. Das untere Ende, das eine Unterstützungszone
markiert, notiert aktuell bei 570 Zählern. Solange sich der Index in diesem Kanal
bewegt, ist die Welt in Ordnung.

Entscheidend sind aus kurzfristiger Sicht nun der Widerstand bei 645 (blau) und
die Unterstützung bei 580 Punkten (rot). Wird der erst genannte übersprungen,
wird die Aufwärtsbewegung wohl fortgesetzt und dürfte sogar an Dynamik
gewinnen. Fällt die Unterstützung, dürfte die Aufwärtsphase als unterbrochen
gelten. Das Szenario einer Seitwärtsbewegung wird dann wahrscheinlicher.


Bedeutende Widerstandszonen befinden sich außerdem bei 700, bei 750 und
beim Allzeithoch von 800 Punkten. Unterstützung findet der Index bei 520, bei 480
und bei 380 Zählern.

Auf die aktuelle Konsolidierung verweist die Markttechnik. Der
200-Tage-Durchschnitt zeigt zusammen mit dem 21er-AMA und dem Aroon auf
einen Seitwärtsmarkt. Ein Verkaufssignal ist dem Trendfolgeindikator MACD zu
entnehmen. Augenblicklich ist jedoch der schnell schwingende
ProjectionOscillator bedeutender. Das Signal des für den kurzfristigen Horizonts
anzuwendenden Oszillators lautet "Kaufen".

Fazit: Die technische Verfassung ist derzeit aussichtsreich. Der Trendkanal sollte
den Index in höhere Kursregionen führen. Der Widerstand bei 645 muß dazu
aber geknackt werden. Wird der Trendkanal gebrochen, ist das positive Szenario
nicht mehr aufrecht zu erhalten.